Neurons and glial cells acquire a senescent signature after repeated mild traumatic brain injury in a sex-dependent manner

Nicole Schwab, Daria Taskina, Emily Leung, Brendan T. Innes, Gary D. Bader, Lili‐Naz HazratiFrontiers in Neuroscience 2022 · DOI

TL;DR

This study reveals that repeated mild traumatic brain injuries (rmTBI) induce cellular senescence in both neurons and glial cells, contributing to cognitive dysfunction. Intriguingly, these effects and the response to senolytic drugs are sex-dependent, suggesting personalized therapeutic strategies are needed for TBI.

What Problem Does This Paper Address?

Mild traumatic brain injury (mTBI), especially when repeated, is a significant public health concern linked to long-term neurological issues and neurodegenerative diseases. However, the underlying mechanisms driving these chronic symptoms remain poorly understood, and effective treatments are lacking. This paper investigates cellular senescence – a state of irreversible cell cycle arrest accompanied by a pro-inflammatory secretome – as a potential key player in the persistent brain dysfunction following rmTBI. The authors also explore whether these mechanisms and potential treatments differ between sexes.

Methods

The researchers employed a mouse model of repeated mild traumatic brain injury (rmTBI) using a closed-skull impactor. They induced three injuries separated by 24-hour intervals. Following injury, they conducted a battery of neurobehavioral tests, including the light-dark box test for anxiety-like behaviors and the Morris Water Maze (MWM) for spatial learning and memory.

To investigate the underlying cellular mechanisms, they used:

  • Histology and Immunohistochemistry: To visualize and quantify markers of DNA damage (γH2AX), astrogliosis (GFAP), and microglial activation (Iba-1) in brain tissue.
  • Western Blotting and Dot Blotting: To measure protein levels of key senescence markers (p16, p21), DNA damage response proteins (γH2AX, DNA2, 53BP1), and components of the cGAS-STING pathway (cGAS, STING, IRF3, HMGB1). They also assessed oxidative DNA damage and R-loop formation.
  • Single-cell RNA sequencing (scRNAseq): This was a crucial technique to comprehensively analyze gene expression changes at the individual cell level across different cell types (neurons, astrocytes, oligodendrocytes, immune cells, vascular cells) in the injured brain. This allowed for the identification of enriched pathways related to senescence, DNA damage, and inflammation in specific cell populations.
  • Senolytic Drug Treatment: The senolytic drug ABT263, which targets senescent cells, was administered to assess its impact on senescence markers and behavioral outcomes.

Datasets

The study utilized data generated from experiments on C57BL/6 mice. The scRNAseq data was deposited in online repositories, with GEO accession numbers provided for reference (GSM6680914, GSM6680915, GSM6680916, and GSM6680917). No new benchmarks were introduced; rather, existing mouse models and established behavioral and molecular assays were employed.

Key Insights and Ideas

  • Cellular Senescence as a Post-TBI Mechanism: The study provides strong evidence that rmTBI triggers cellular senescence in both neurons and glial cells, characterized by DNA damage, cell cycle arrest markers (p16, p21), and inflammatory signaling (cGAS-STING pathway). This suggests senescence is not just a consequence of aging but can be actively induced by injury.
  • Sex Differences in TBI Response: A major finding is the significant sex-dependent nature of TBI's impact. While both sexes showed signs of senescence, females exhibited higher levels of DNA damage but paradoxically lower levels of p16 and reduced cGAS-STING signaling compared to males. This hints at different coping mechanisms or vulnerabilities.
  • Senolytics Show Sex-Specific Efficacy: The senolytic drug ABT263 effectively reduced senescence markers and improved cognitive function in male mice post-TBI. However, it was not therapeutic in females and, intriguingly, even increased p16 expression in non-injured females, suggesting potential harm or a complex interaction.
  • Neurons Can Exhibit Senescence-Like Signatures: The scRNAseq data revealed senescence-related pathways enriched in various neuronal subtypes, challenging the notion that post-mitotic neurons cannot become senescent. This opens new avenues for understanding neuronal dysfunction after injury.
  • Senescence and Proteinopathy Link: The study identified enriched pathways related to proteinopathies (like Alzheimer's and Parkinson's disease) in senescent neurons, suggesting that TBI-induced senescence might prime the brain for neurodegenerative processes.

Key Results

  • rmTBI mice showed prolonged righting reflexes, astrogliosis, and impaired performance in the MWM and light-dark tests one week post-injury.
  • Cortical and hippocampal tissues revealed increased DNA damage (double-strand breaks, oxidative damage, R-loops), elevated p16 and p21, and activated cGAS-STING signaling in rmTBI mice.
  • Females exhibited higher DNA damage but lower p16 and cGAS-STING signaling compared to males.
  • scRNAseq of male rmTBI brains showed activation of DNA damage response, cellular senescence, and pro-inflammatory markers in neurons and glial cells.
  • ABT263 treatment significantly reduced p21 in male rmTBI mice and improved their MWM performance.
  • ABT263 did not reduce senescence markers in female rmTBI mice and paradoxically increased p16 in females.

Limitations and Future Work

  • Sex Differences in Senolytic Response: The most significant limitation highlighted is the sex-specific efficacy of ABT263. While effective in males, it was not beneficial and potentially detrimental in females. This necessitates further investigation into the underlying mechanisms and the development of sex-specific senolytic strategies.
  • Generalizability of Senolytic Drug: The study used a single senolytic drug (ABT263) targeting only the BCL-2 SCAP network. The authors suggest that senescent cells often employ multiple SCAP networks, implying that drugs targeting multiple pathways might be more effective.
  • Long-Term Effects: The study focused on the effects one week post-injury. Future work should investigate the long-term consequences of TBI-induced senescence and the sustained effects of senolytic treatments.
  • Estrogen's Role: The authors hypothesize that reduced estrogen levels in females post-injury might contribute to increased DNA damage and senescence. Future studies could directly investigate the role of sex hormones in TBI-induced senescence and sex differences.
  • Clinical Translation: While promising, the findings are from a mouse model. Translating these insights into effective human therapies requires further research and clinical trials. The authors emphasize the need for personalized and sex-specific approaches in future TBI research and treatment.

Summary updated

Abstract

Mild traumatic brain injury (mTBI) is an important public health issue, as it can lead to long-term neurological symptoms and risk of neurodegenerative disease. The pathophysiological mechanisms driving this remain unclear, and currently there are no effective therapies for mTBI. In this study on repeated mTBI (rmTBI), we have induced three mild closed-skull injuries or sham procedures, separated by 24 h, in C57BL/6 mice. We show that rmTBI mice have prolonged righting reflexes and astrogliosis, with neurological impairment in the Morris water maze (MWM) and the light dark test. Cortical and hippocampal tissue analysis revealed DNA damage in the form of double-strand breaks, oxidative damage, and R-loops, markers of cellular senescence including p16 and p21, and signaling mediated by the cGAS-STING pathway. This study identified novel sex differences after rmTBI in mice. Although these markers were all increased by rmTBI in both sexes, females had higher levels of DNA damage, lower levels of the senescence protein p16, and lower levels of cGAS-STING signaling proteins compared to their male counterparts. Single-cell RNA sequencing of the male rmTBI mouse brain revealed activation of the DNA damage response, evidence of cellular senescence, and pro-inflammatory markers reminiscent of the senescence-associated secretory phenotype (SASP) in neurons and glial cells. Cell-type specific changes were also present with evidence of brain immune activation, neurotransmission alterations in both excitatory and inhibitory neurons, and vascular dysfunction. Treatment of injured mice with the senolytic drug ABT263 significantly reduced markers of senescence only in males, but was not therapeutic in females. The reduction of senescence by ABT263 in male mice was accompanied by significantly improved performance in the MWM. This study provides compelling evidence that senescence contributes to brain dysfunction after rmTBI, but may do so in a sex-dependent manner.
BibTeX
@inproceedings{schwab2022neurons,
  author = {Nicole Schwab and Daria Taskina and Emily Leung and Brendan T. Innes and Gary D. Bader and Lili‐Naz Hazrati},
  title = {{Neurons and glial cells acquire a senescent signature after repeated mild traumatic brain injury in a sex-dependent manner}},
  booktitle = {Frontiers in Neuroscience},
  year = {2022},
  doi = {10.3389/fnins.2022.1027116},
}
Figure